Clinical and Prognostic Significance of <i>CEBPA</i> Mutations in Myelodysplastic Syndromes.

Nominally significant adverse associations were observed in eight strata on unadjusted testing: an age below the cohort median of 72 years (HR 2.08, 95% CI 1.28–3.38; p = 0.003), an age of 72 years or older (HR 1.98, 95% CI 1.33–2.96; p < 0.001), female sex (HR 2.21, 95% CI 1.18–4.16; p = 0.013), male sex (HR 1.91, 95%

also in 7,732 other papers